A very firm handshake: biotech's growing negotiating power

@article{Thiel2005AVF,
  title={A very firm handshake: biotech's growing negotiating power},
  author={K. Thiel},
  journal={Nature Biotechnology},
  year={2005},
  volume={23},
  pages={1221-1226}
}
  • K. Thiel
  • Published 2005
  • Medicine, Biology
  • Nature Biotechnology
Even small biotech companies are taking more control of their product development as cash, competition, and other factors combine to bolster their negotiating power. 
7 Citations

Figures, Tables, and Topics from this paper

Minimizing leakage of value from R&D alliances
  • Andrew Jones
  • Business, Medicine
  • Nature Reviews Drug Discovery
  • 2007
  • 11
Shift toward early-stage deals favors biotechs
  • 4
Biotechnology financing, not acquisitions, for filling the pharma pipeline – a sustaining strategy
  • P. Fernandes
  • Biology, Medicine
  • Expert opinion on drug discovery
  • 2007
  • 1
Ensuring Quality Science From “R” to “D”: An Optimal Adoption Strategy for In-Licensing of Pharmaceutical Innovation
  • G. Zhao, Wen Chen
  • Business, Computer Science
  • IEEE Transactions on Engineering Management
  • 2011
  • 5
  • Highly Influenced
The art of antibody process development.
  • 49
Immunopharmacology: utilizing antibodies as ion channel modulators
  • 8

References

SHOWING 1-8 OF 8 REFERENCES
Getting real about valuations in biotech
  • 24
Goodbye Columbus! New NRDOs forego discovery
  • K. Thiel
  • Medicine, Biology
  • Nature Biotechnology
  • 2004
  • 8
The price of innovation: new estimates of drug development costs.
  • 3,865
  • PDF
Critical Factors for Alliance Formation: Insights from the Deloitte Research Biotech Alliance Survey (Deloitte Research
  • 2005
Deal Statistics Quarterly,
  • In Vivo: The Business & Medicine Report,
  • 2005
Crisis? What Crisis? A Fresh Diagnosis of Big Pharma’s R&D Productivity
  • Crunch (Marakon Associates,
  • 2004
New estimates of drug development costs.
  • R. Frank
  • Business, Medicine
  • Journal of health economics
  • 2003
  • 189
  • PDF
Pfizer ’ s Funk